In the non‐amyloidogenic pathway, the Alzheimer's amyloid precursor protein (APP) is
cleaved within the amyloid‐β domain by α‐secretase precluding deposition of intact amyloid …

The most important therapeutic effect of cholinesterase inhibitors (ChEI) on approximately
50% of Alzheimer's disease (AD) patients is to stabilize cognitive function at a steady level …

Deficits in cholinergic function contribute to the pathology of Alzheimer's disease (AD),
affecting cognition, behaviour and activities of daily living. Pharmacological intervention …

Treatment of Alzheimer's disease has been dominated by the use of acetylcholinesterase
(AChE) inhibitors. These drugs compensate for the death of cholinergic neurons and offer …

The possibility to understand the causes and treat the symptoms of Alzheimer's disease
patients is still a great challenge. The triggering events leading to the selective …

Cholinergic dysfunction is a consistent feature of Alzheimer's disease, and the
interrelationship between β-amyloid deposits, inflammation and early cholinergic cell loss is …

Background Treatment with cholinesterase inhibitors improves cognition in patients with
Alzheimer disease (AD). In studies designed with a washout period at the end of the study …

Potentiation of central cholinergic activity has been proposed as a therapeutic approach for
improving the cognitive function in patients with Alzheimer's disease (AD). Increasing the …

Acetylcholinesterase (AChE) activities in CNS physiopathology are increasingly diverse and
range from neuritogenesis, through synaptogenesis, to enhancement of amyloid fiber …

We have investigated the effect of ganstigmine (CHF2819), a novel geneserine derived
acetylcholinesterase (AChE) inhibitor, on the expression and metabolism of the amyloid …